We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.
- Authors
Ciceroni, C; Bonelli, M; Mastrantoni, E; Niccolini, C; Laurenza, M; Larocca, L M; Pallini, R; Traficante, A; Spinsanti, P; Ricci-Vitiani, L; Arcella, A; De Maria, R; Nicoletti, F; Battaglia, G; Melchiorri, D
- Abstract
Drug treatment of malignant gliomas is limited by the intrinsic resistance of glioma stem cells (GSCs) to chemotherapy. GSCs isolated from human glioblastoma multiforme (GBM) expressed metabotropic glutamate receptors (mGlu3 receptors). The DNA-alkylating agent, temozolomide, killed GSCs only if mGlu3 receptors were knocked down or pharmacologically inhibited. In contrast, mGlu3 receptor blockade did not affect the action of paclitaxel, etoposide, cis-platinum, and irinotecan. mGlu3 receptor blockade enabled temozolomide toxicity by inhibiting a phosphatidylinositol-3-kinase/nuclear factor-κB pathway that supports the expression of O6-methylguanine-DNA methyltransferase (MGMT), an enzyme that confers resistance against DNA-alkylating agents. In mice implanted with GSCs into the brain, temozolomide combined with mGlu3 receptor blockade substantially reduced tumor growth. Finally, 87 patients with GBM undergoing surgery followed by adjuvant chemotherapy with temozolomide survived for longer time if tumor cells expressed low levels of mGlu3 receptors. In addition, the methylation state of the MGMT gene promoter in tumor extracts influenced survival only in those patients with low expression of mGlu3 receptors in the tumor. These data encourage the use of mGlu3 receptor antagonists as add-on drugs in the treatment of GBM, and suggest that the transcript of mGlu3 receptors should be measured in tumor specimens for a correct prediction of patients' survival in response to temozolomide treatment.
- Subjects
GLUTAMIC acid; GLIOMAS; STEM cells; GENE expression; GLIOBLASTOMA multiforme; DRUG therapy
- Publication
Cell Death & Differentiation, 2013, Vol 20, Issue 3, p396
- ISSN
1350-9047
- Publication type
Article
- DOI
10.1038/cdd.2012.150